Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications association host pharmacodynamic effects virologic response pegylated interferon alfa
… for Pharmacoepidemilogy, the American Public Health Association, the Academy of Managed Care Pharmacy, and the …
Dana DiBenedetti Patient-Centered Outcomes Assessment Women's Health Psychiatry Men's Health Hematology Diabetes & Endocrine Disorders Dermatology CNS/Neurology Telecommuter - USA PhD, Clinical Psychology MS, Clinical Psychology Oklahoma State University …
Developing New Skillsets LaStella displays notes of encouragement and positive feedback she has received. I’ve always been interested in solving problems and helping people, so that is what made RTI-HS a great place for me after finishing my master’s …
… Na’ngono is a member of the British Oncology Pharmacy Association. …
Christina Darden Surveys and Observational Studies Headquarters - Research Triangle Park, North Carolina, USA BS, Chemistry North Carolina State University, Raleigh, NC Christina M. Darden is a Senior Director in the Surveys and Observational Studies …
Multinational Observational Study in Chronic Idiopathic Urticaria OPPORTUNITY Our client wanted to measure real-world treatment patterns, healthcare resource use, HRQOL, and indirect burden associated with chronic idiopathic urticaria (CIU). They needed …
Navigating EU Joint Clinical Assessments and Joint Scientific Consultations From January 2025 Onward
Navigating EU Joint Clinical Assessments and Joint Scientific Consultations From January 2025 Onward Emma Hawe, MSc Head, Data Analytics and Design Strategy RTI Health Solutions Transcript: What Do We Need to Know About Joint Clinical Assessments (JCAs)? …
Highlights From AMCP 2024 on the New Dossier Format Version 5.0 Share on: May 1, 2024 Image Contributor: Jennifer Alkire, PharmD, Senior Associate, Value & Access, RTI Health Solutions Jennifer attended the AMCP 2024 conference and brings back these …
… learn How to map the identifiability conditions of causal effects in the design of an RCT and in an observational study …
… companies responding on several levels. Portfolio-Level Response Because small molecules or multiple-indication … large-molecule drugs or biologicals instead. Disease-Level Response Companies might be thinking of prioritising the …